Liver Cancer Clinical Trials
Clinical trials are studies conducted on volunteers using investigational treatments or methods. The decision to enroll in a trial should be based on concrete information and eligibility depends on many factors.
For more information about HCC clinical trials in your area, visit www.clinicaltrials.gov.
Discuss the advantages, disadvantages, and side effects of treatment options with your doctor.
Ask your doctor about the possibility of using experimental therapies and eligibility to participate in clinical trials. If you want to participate in a clinical trial, ask what is the phase of the trial.
Consider seeking a second opinion if your health insurance allows you the option to do so.
LIVER CANCER CLINICAL TRIALS (featured listings)
Blue Faery does not endorse, sponsor or recommend any specific clinical trial. An asterisk indicates a paid listing.
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism (Tumor HI)*
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI). Detailed Description This study will include participants who are suffering from low blood sugar related symptoms (hypoglycemia) due to over-production of hormones (e.g. insulin or similar substances) by certain non-removable tumors that cannot be treated satisfactorily with available treatment. Every study participant will receive ersodetug doses weekly for 8 weeks alongside their usual treatments for hypoglycemia at a dose of 9 mg/kg. The study is divided into 3 periods: Screening (up to 4 weeks), Treatment (8 weeks) and either End of Study Follow-up (approximately up to 20 weeks after the last dose) or optional Open Label Extension (OLE) phase (up to 3 years). This study is being conducted at approximately 10-15 study sites in approximately 5 countries. The study will enroll approximately 16 participants, all with a diagnosis of tumor HI (insulin- or IGF producing tumors).
Official Title: A Phase 3, Single-Arm, Open-label, Pivotal Study to Evaluate the Efficacy and Safety of Ersodetug Compared to Baseline in Patients With Inadequately Controlled Hypoglycemia Due to Tumor Hyperinsulinism (Tumor HI)
Condition: Tumor Hyperinsulinism (Tumor HI)
Intervention/Treatment: Drug: Ersodetug
Phase: Phase 3
Study Type: Interventional (Clinical Trial)
Study Design: A Phase 3, Single-Arm, Open-label, Pivotal Study
Primary Purpose: Treatment
For more information, contact Dana Jastrow, Dir. Patient Affairs
Email: patient-affairs@rezolutebio.com
Business Phone: (630) 901-7102
Website:http://rezolutebio.com/
Rezolute, Inc.
275 Shoreline Drive, Suite #500,
Redwood City, CA 94065,
United States
Listed on 2/24/26
This expanded access program is intended to provide ersodetug, an investigational drug, to eligible participants who suffer from inadequately controlled hypoglycemia due to tumor-associated hyperinsulinism and are unable to participate in ersodetug clinical trial. Participation is open to participants who meet the eligibility criteria and for whom access to the investigational drug is deemed appropriate by the treating physician. Official Title Intermediate-Size Cohort EAP for Ersodetug in Patients With Refractory Hypoglycemia Due to Tumor-Associated Hyperinsulinism (Tumor HI) Who Are Unable to Participate in a Clinical Trial
Official Title: Intermediate-Size Cohort EAP for Ersodetug in Patients With Refractory Hypoglycemia Due to Tumor-Associated Hyperinsulinism (Tumor HI) Who Are Unable to Participate in a Clinical Trial
Condition: Tumor Hyperinsulinism (Tumor HI)
Intervention/Treatment: Drug: Ersodetug
Phase: Expanded Access
Study Type: Expanded Access
Study Design: Expanded Access
For more information, contact Dana Jastrow, Dir. Patient Affairs
Email: patient-affairs@rezolutebio.com
Business Phone: (630) 901-7102
Website:http://rezolutebio.com/
Rezolute, Inc.
275 Shoreline Drive, Suite #500,
Redwood City, CA 94065,
United States
Listed on 2/24/26
This study is designed to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab. The study started in December 2024 and has an estimated completion date of September 2027. People who have liver cancer might be able to join if:
They are 18 years of age or older.
They cannot undergo surgery for liver cancer, and the cancer has spread to tissues near the liver (locally advanced disease) or to other organs (metastatic disease).
They have not received treatment for the cancer.
They have not received treatment against IL-27.
Official Title: A Randomized Phase 2 Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma (HCC)
Intervention/Treatment: The study has 3 arms and will test 3 different interventions: • Arm A: Casdozokitug (700 mg) + toripalimab + bevacizumab • Arm B: Casdozokitug (1,400 mg) + toripalimab + bevacizumab • Arm C: Toripalimab + bevacizumab
Phase: Phase II
Study Type: Interventional
Study Design: Randomized, Open Label
Primary Purpose: Treatment
For more information, contact the Clinical Operations Team, Coherus Oncology
Email: clinicaltrials@coherus.com
Business Phone: (800) 794-5434
Website: http://www.coherus.com
Coherus Oncology
333 Twin Dolphin Drive,
Suite 600, Redwood City,
CA 94065,
United States
Listed on 8/13/2025
The purpose of this study is to assess the safety and tolerability of ET140203 T cells in pediatric patients with Alpha-fetoprotein (AFP)-positive/Human Leukocyte Antigen (HLA) A-2-positive Relapsed/Refractory Hepatoblastoma (HB), Hepatocellular Malignant Neoplasm, Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC) and to determine the recommended Phase 2 dose (RP2D). ET140203 T cells are autologous T cells engineered to specifically recognize and kill AFP/HLA-A2 positive liver cancer cells.
Official Title: An Open-Label, Dose Escalation, Phase I/II Clinical Trial of ET140203 T Cells in Pediatric Subjects With Relapsed/Refractory Hepatoblastoma (HB), Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC)
Condition: Hepatoblastoma (HB), Hepatocellular Malignant Neoplasm, Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC)
Intervention/Treatment: ET140203 autologous T cells
Phase: Phase I/II
Study Type: Interventional (Clinical Trial)
Study Design: Sequential Assignment, Open Label
Primary Purpose: Treatment
For more information, please reach out:
Email: eurekaconnectme@eurekainc.com
Website: https://www.eurekaconnectme.com
Phone (510) 722-8719
Business Phone: (510) 654-7045
Eureka Therapeutics, Inc.
5858 Horton Street, Suite 170
Emeryville, CA 94608
United States
Map It
Listed on 11/8/21
The purpose of this study is to assess the safety and tolerability of ECT204 T cells in adult patients with glypican-3 (GPC3) positive hepatocellular carcinoma (HCC) and to determine the recommended Phase 2 dose (RP2D). ECT204 T cells are autologous T cells engineered to specifically recognize and kill GPC3 positive liver cancer cells.
Official Title: An Open-Label, Dose-Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy in Adults With Advanced Hepatocellular Carcinoma (HCC) (ARYA-3)
Condition: Advanced hepatocellular carcinoma
Intervention/Treatment: ECT204 T cells
Phase: Phase I/II
Study Type: Interventional (Clinical Trial)
Study Design: Sequential Assignment, Open Label
Primary Purpose: Treatment
For more information, reach out
Email: eurekaconnectme@eurekainc.com
Website: https://www.eurekaconnectme.com
Phone (510) 722-8719
Business Phone: (510) 654-7045
Eureka Therapeutics, Inc.
5858 Horton Street, Suite 170
Emeryville, CA 94608
United States
Map It
Listed on 7/22/21
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar)
This early phase I trial studies the side effects of autologous dendritic cells and a vaccine called Prevnar in treating patients with liver cancer that cannot be removed by surgery after undergoing standard high-dose external beam radiotherapy. Autologous dendritic cells are immune cells generated from patients' own white blood cells that are grown in a special lab and trained to stimulate the immune system to destroy tumor cells. A pneumonia vaccine called Prevnar may also help stimulate the immune system. Giving autologous dendritic cells and Prevnar to patients with live cancer after radiotherapy may help doctors determine if it is possible to stimulate the body's own immune system to fight against the tumor, and to see if this immune stimulation can be done safely.
Condition: Hepatocellular carcinoma
Intervention: Combination of external beam radiation therapy, pneumonia (Prevnar) vaccine and autologous dendritic cells
Phase: Phase 1
Study Type: Interventional (Clinical Trial)
Study Design: Single arm, open label
Primary Purpose: Treatment
For more information, contact Dr. Lewis Roberts, Director, Hepatobiliary Neoplasia Clinic
Email: Roberts.Lewis@mayo.edu
Website: https://www.mayo.edu/research/faculty/roberts-lewis-r-m-b-ch-b-ph-d/bio-00084430
Phone (507) 266-3239
Mayo Clinic
200 First Street SW
Rochester, MN 55905
United States
Map It
Listed on 9/22/20